Patrick Zweidler-McKay
Chief Medical Officer NEOK Bio
Seminars
Tuesday 13th October 2026
Presentation Preview: The Emerging Wave of Bispecific ADCs: Breaking Down Design & Rationale for NEOK001 & NEOK002
- Delving into the IND-enabling profiles of bispecific ADCs NEOK001 and 002, emphasizing advantages over monospecific ADCs
- Explaining the unique characteristics of NEOK001 targeting B7-H3+ROR1 including higher need for differentiation amongst B7-H3 ADC landscape
- Breaking down early clinical development strategy and lessons learned from ongoing Phase I bispecific ADC trials
